BRÈVE publiée le 06/07/2026 à 07:05, il y a 2 mois 12 jours ReproNovo Begins EU Phase 2 Trial for Embryo Implantation Treatment ReproNovo RPN-002 Embryo Implantation NORDIC Trial Assisted Reproductive Technology
BRÈVE publiée le 06/07/2026 à 07:05, il y a 2 mois 12 jours ReproNovo lance un essai clinique de phase 2 dans l'UE pour son traitement d'implantation d'embryons. ReproNovo RPN-002 Implantation D'embryons Essai Nordique Techniques De Procréation Assistée
COMMUNIQUÉ DE PRESSE publié le 06/07/2026 à 07:00, il y a 2 mois 12 jours ReproNovo Announces First Participant Dosed In EU Phase 2 Trial Of RPN-002 Embryo Implantation ReproNovo doses first participant in EU Phase 2 trial of RPN-002 for embryo implantation, aiming to increase IVF success rates with oxytocin receptor antagonist ReproNovo RPN-002 Embryo Implantation EU Phase 2 Trial IVF Success
BRÈVE publiée le 20/03/2026 à 13:05, il y a 5 mois 29 jours ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
BRÈVE publiée le 20/03/2026 à 13:05, il y a 5 mois 29 jours ReproNovo nomme Mark Altmeyer président du conseil d'administration Biopharmaceutique Direction ReproNovo Mark Altmeyer Fécondité
COMMUNIQUÉ DE PRESSE publié le 20/03/2026 à 13:00, il y a 5 mois 29 jours REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRÈVE publiée le 30/09/2025 à 07:05, il y a 11 mois 18 jours ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
BRÈVE publiée le 30/09/2025 à 07:05, il y a 11 mois 18 jours ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
COMMUNIQUÉ DE PRESSE publié le 30/09/2025 à 07:00, il y a 11 mois 18 jours ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRÈVE publiée le 01/07/2025 à 07:05, il y a 1 année 2 mois ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
Publié le 17/09/2026 à 17:40, il y a 19 heures 43 minutes Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Publié le 17/09/2026 à 17:40, il y a 19 heures 43 minutes Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Publié le 18/09/2026 à 06:30, il y a 6 heures 53 minutes GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Publié le 18/09/2026 à 00:55, il y a 12 heures 28 minutes Tectonic Metals Announces Results of the 2026 Annual General Meeting
Publié le 18/09/2026 à 00:25, il y a 12 heures 58 minutes CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Publié le 17/09/2026 à 22:15, il y a 15 heures 8 minutes Rocky Shore Gold Announces Non-Brokered Private Placement
Publié le 18/09/2026 à 13:17, il y a 6 minutes Conversion to registered shares with a new ISIN DE000A41YHG1 is proceeding as planned – temporary discrepancies in portfolio displays are possible
Publié le 18/09/2026 à 13:10, il y a 13 minutes United Arab Emirates Law Enforcement Arrests Money Laundering Gang Leader
Publié le 18/09/2026 à 13:01, il y a 22 minutes Emerald Horizon draws strong interest with SMRX in Berlin
Publié le 18/09/2026 à 12:35, il y a 48 minutes mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
Publié le 18/09/2026 à 12:32, il y a 51 minutes EQS-Adhoc: Wolford AG: Mandate of Ralf Polito as Member of the Management Board extended
